RBR-7k3nv44进行中(未招募)1 期
In search of protection correlations for Dengue (Dengue Protect study): Comparison of the effects from Dengue infection with the effects from the inoculation of Qdenga vaccine in different age groups - PROTECT Dengue Protection correlations for Dengue
niversidade Federal de Minas Gerais0 个研究点开始时间: 2024年8月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 90Y(—)
入选标准
- •Vaccination cohort: Participants between 18 to 90 years of age who agree to participate in the study. Absence of an acute clinical condition at the time of vaccination. Infected cohort: Participants under 18 yeas old. Participants with more than 5 days of symptoms. Participants who do not agree to sign the informed consent form. Participants who are not available to carry out the planned study visits
排除标准
- •Vaccination cohort: Participants under 18 years old. Participants who are not available to carry out the planned visits of the study. Participants who do not agree to sign the informed consent form. Positive beta Human Chorionic Gonadotropin on the day of vaccination, in the case of women of reproductive potential. Participants who are pregnant or planning to become pregnant within the next 3 months after the last vaccine dose. Participants breastfeeding. Participant with a known or suspected immune system defect that may influence the immunological response to the vaccine, such as participants with congenital or acquired immunodeficiency, including human immunodeficientcy virus infection, post-organ transplant status or immunosuppressive therapy within 4 weeks prior to Visit 1. Therapy Immunosuppressive is defined as chronic administration of prednisone (more than 14 days) or equivalent more or equal than 2 miligramas por kilo por dia in the 4 weeks prior to study entry, radiotherapy or immunosuppressive cytotoxic drugs or monoclonal antibodies in the 3 previous years, topical and inhaled steroids are permitted. Infected cohort: Participants with more than 5 days of symptoms. Participants who do not agree to sign the Informed consent form. Participants who are not available to carry out the planned study visits
研究者
相似试验
已完成
1 期
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy AdultsDengueNCT01931176National Institute of Allergy and Infectious Diseases (NIAID)14
已完成
不适用
A trial to assess risk of dengue and evaluate a mosquito control intervention in northeastern ThailandDengueInfections and InfestationsISRCTN73606171orwegian University of Life Sciences539
已完成
1 期
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy AdultsDengueNCT00712803National Institute of Allergy and Infectious Diseases (NIAID)29
已完成
1 期
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy AdultsDengue FeverNCT00831012National Institute of Allergy and Infectious Diseases (NIAID)56
已完成
1 期
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months ApartDengueNCT01782300National Institute of Allergy and Infectious Diseases (NIAID)48
